Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211196 | 0.93 | EDNRB (0.56) | EDNRBEDNRA | |
| SCHEMBL7318413 | 0.92 | EDNRB (0.45) | EDNRB | |
| SCHEMBL7317941 | 0.92 | EDNRB (0.45) | EDNRB | |
| SCHEMBL7307894 | 0.91 | EDNRB (0.45) | EDNRB | |
| SCHEMBL7209287 | 0.88 | EDNRA (0.49) | EDNRBEDNRA | |
| SCHEMBL6288973 | 0.85 | EDNRB (0.53) | EDNRBEDNRA | |
| SCHEMBL7223045 | 0.80 | EDNRB (0.47) | EDNRBEDNRA | |
| SCHEMBL6293249 | 0.78 | EDNRB (0.44) | EDNRB | |
| SCHEMBL6292822 | 0.77 | EDNRB (0.43) | EDNRB | |
| SCHEMBL6288929 | 0.77 | EDNRB (0.43) | EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6387915-B2 | VASODILATION | PFIZER INC. | 2002-05-14 | — | — | US | claimed |
| US-20020019408-A1 | New isoxazole-sulfonamide endothelin antagonists | BANKS BERNARD JOSEPH (GB) | 2002-02-14 | — | — | US | claimed |
| US-6610518-B2 | Using Cytochrome p450 | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-6387915-B2 | VASODILATION | PFIZER INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020019408-A1 | New isoxazole-sulfonamide endothelin antagonists | BANKS BERNARD JOSEPH (GB) | 2002-02-14 | — | — | US | disclosed |
| US-20020012977-A1 | Enzymatic oxidations | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1160248-A1 | N-(Isoxazol-5-yl)-sulfonamide derivatives and their use as endothelin antagonists | PFIZER INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1160331-A1 | Enzymatic oxidations | Pfizer Limited (GB) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019408-A1 | New isoxazole-sulfonamide endothelin antagonists | EDNRB, EDNRA, ECE1 | EDNRB 1/4885EDNRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.